Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

Elicio Therapeutics, Inc. (ANGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/12/2023 3 Chudnovsky Yekaterina (Director) has filed a Form 3 on Elicio Therapeutics, Inc.
06/12/2023 3 Haqq Christopher (See Remarks) has filed a Form 3 on Elicio Therapeutics, Inc.
06/07/2023 3 DeMuth Peter (Chief Scientific Officer) has filed a Form 3 on Elicio Therapeutics, Inc.
06/07/2023 3 Segal Assaf (Director) has filed a Form 3 on Elicio Therapeutics, Inc.
06/07/2023 3 RUFFOLO ROBERT R (Director) has filed a Form 3 on Elicio Therapeutics, Inc.
06/07/2023 3 Matthies Annette (Chief Business Officer) has filed a Form 3 on Elicio Therapeutics, Inc.
06/07/2023 3 ADAMS JULIAN (Director) has filed a Form 3 on Elicio Therapeutics, Inc.
06/07/2023 3 Connelly Robert (CEO, President and Director) has filed a Form 3 on Elicio Therapeutics, Inc.
06/07/2023 3 Ashe Carol Gail (Director) has filed a Form 3 on Elicio Therapeutics, Inc.
06/05/2023 4 Piekos Brian (CFO) has filed a Form 4 on Elicio Therapeutics, Inc.
Txns: Granted 75,484 options to buy @ $10, valued at $754.8k
06/05/2023 3 Piekos Brian (CFO) has filed a Form 3 on Elicio Therapeutics, Inc.
07/11/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/13/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/13/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/13/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/13/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/27/2022 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
05/27/2022 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
05/27/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/25/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/23/2022 4 Nissenson Allen (Director) has filed a Form 4 on Angion Biomedica Corp.
Txns: Bought 7,346 shares @ $1.16, valued at $8.5k
Bought 2,037 shares @ $1.18, valued at $2.4k
03/04/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/04/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/04/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/04/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/29/2021 4 Venkatesan Jay (See Remarks) has filed a Form 4 on Angion Biomedica Corp.
Txns: Bought 66,907 shares @ $2.5486, valued at $170.5k
Bought 210,337 shares @ $2.6617, valued at $559.9k
12/22/2021 4 Venkatesan Jay (See Remarks) has filed a Form 4 on Angion Biomedica Corp.
Txns: Bought 3,527 shares @ $2.5449, valued at $9k
12/21/2021 4 Neylan John F. (See Remarks) has filed a Form 4 on Angion Biomedica Corp.
Txns: Sold 358 shares @ $2.6201, valued at $938
12/20/2021 4 Venkatesan Jay (See Remarks) has filed a Form 4 on Angion Biomedica Corp.
Txns: Bought 27,883 shares @ $2.5461, valued at $71k
Bought 13,742 shares @ $2.5439, valued at $35k
12/17/2021 4 Venkatesan Jay (See Remarks) has filed a Form 4 on Angion Biomedica Corp.
Txns: Paid exercise price by delivering 41,091 shares @ $13.78, valued at $566.2k
Bought 77,604 shares @ $2.4091, valued at $187k
12/16/2021 4 CURHAN GREGORY S (See Remarks) has filed a Form 4 on Angion Biomedica Corp.
Txns: Bought 4,000 shares @ $2.37, valued at $9.5k
12/15/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/07/2021 4 Goldberg Itzhak (See Remarks) has filed a Form 4 on Angion Biomedica Corp.
Txns: Sold 32,118 shares @ $3.3539, valued at $107.7k
12/03/2021 4 Goldberg Itzhak (See Remarks) has filed a Form 4 on Angion Biomedica Corp.
Txns: Sold 38,867 shares @ $3.542, valued at $137.7k
Sold 38,800 shares @ $3.5136, valued at $136.3k
Sold 40,215 shares @ $3.3872, valued at $136.2k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy